Nuclera receives £1.14m for eProtein Discovery platform

GBP pound sterling funding

Biotech Nuclera has been awarded two Innovate UK grants totalling £1.14 ($1.4) million to further develop its eProtein Discovery platform.

The funding is made up of a flexible, agile, scalable, and sustainable technologies (FASST) grant awarded in collaboration with DeepMirror, and an Engineering Biology grant.

The FASST grant is part of the Innovate UK Transforming Medicines Manufacturing (TMM) programme and has been designed to support and grow the UK’s capabilities in manufacturing medicines by developing first-of-a-kind technologies to accelerate patient access to new drugs and treatments.

Nuclera is one of 48 companies to be awarded the Engineering Biology grant, which aims to use engineering biology to tackle challenges in the fields of health, environment, food production and sustainability. The funding is provided by the UK Research and Innovation (UKRI) Technology Missions Fund and delivered by Innovate UK.

Dr Michael Chen, CEO and co-founder, Nuclera, said: “We look forward to working with DeepMirror, Dr Beis (via Imperial Consultants), and Dr Quigley from Diamond Light Source on both projects.”

Diana Spencer, Senior Digital Content Editor, DDW

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free